KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Change in Cash (2016 - 2025)

Historic Change in Cash for Novavax (NVAX) over the last 17 years, with Q3 2025 value amounting to $14.4 million.

  • Novavax's Change in Cash rose 11343.82% to $14.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$305.2 million, marking a year-over-year decrease of 29244.75%. This contributed to the annual value of -$38.5 million for FY2024, which is 9496.52% up from last year.
  • Latest data reveals that Novavax reported Change in Cash of $14.4 million as of Q3 2025, which was up 11343.82% from -$9.5 million recorded in Q2 2025.
  • In the past 5 years, Novavax's Change in Cash registered a high of $1.4 billion during Q1 2021, and its lowest value of -$711.9 million during Q1 2023.
  • In the last 5 years, Novavax's Change in Cash had a median value of -$82.6 million in 2023 and averaged -$19.2 million.
  • Its Change in Cash has fluctuated over the past 5 years, first soared by 121445.17% in 2021, then tumbled by 137487.33% in 2023.
  • Over the past 5 years, Novavax's Change in Cash (Quarter) stood at -$418.6 million in 2021, then soared by 113.34% to $55.8 million in 2022, then tumbled by 247.88% to -$82.6 million in 2023, then skyrocketed by 47.55% to -$43.3 million in 2024, then surged by 133.2% to $14.4 million in 2025.
  • Its Change in Cash stands at $14.4 million for Q3 2025, versus -$9.5 million for Q2 2025 and -$266.8 million for Q1 2025.